- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01759576
A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function
27 de mayo de 2013 actualizado por: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
An Open-Label, Single-Dose Study to Evaluate JNJ-28431754 Pharmacokinetics, Pharmacodynamics and Safety in Non-Diabetic Subjects With Varying Degrees of Renal Function
The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of canagliflozin (JNJ-28431754) after administration of a single dose to non-diabetic volunteers with normal kidney function and non-diabetic volunteers with varying degrees of kidney impairment (including volunteers with end-stage renal disease requiring hemodialysis).
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
This study will be an open label (all volunteers and study staff know the identity of the assigned treatment), single-dose, multicenter (the study will be conducted at more than one center), parallel-group study (each group of volunteers will be treated at the same time) to assess the pharmacokinetics and pharmacodynamics of canagliflozin (a drug currently being investigated for the treatment of type 2 diabetes mellitus) in volunteers with varying degrees of kidney function.
The study will consist of 3 phases: a screening phase, an open-label treatment phase, and an end-of study (or follow-up) phase.
Volunteers will be assigned to 1 of 5 groups (depending on kidney function): group 1 will have normal kidney function; group 2 will have mild kidney impairment; group 3 will have moderate kidney impairment; group 4 will have severe kidney impairment; and group 5 will comprise volunteers requiring hemodialysis.
Volunteers in groups 1 through 4 will receive a single dose of canagliflozin on Day 1. Volunteers in group 5 will receive a single dose of canagliflozin following dialysis and then, approximately 10 days later, they will receive a second dose before dialysis.
Volunteers in groups 1 through 4 will participate in the study for 27 days.
Volunteers in group 5 will participate in the study for 40 days.
Tipo de estudio
Intervencionista
Inscripción (Actual)
40
Fase
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Florida
-
Orlando, Florida, Estados Unidos
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 79 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Volunteers must have a body mass index (BMI = weight in kg/height in m2) between 20 and 40 kg/m2 (inclusive), and body weight not less than 50 kg
- Volunteers must smoke no more than 10 cigarettes, or 2 cigars, or 2 pipes of tobacco per day for at least 6 months before first study drug administration
Exclusion Criteria:
- History of or currently active illness considered to be clinically significant by the Investigator or any other illness that the Investigator considers should exclude the patient from the study or that could interfere with the interpretation of the study results
- Volunteers with end stage renal disease receiving dialysis treatment other than intermittent hemodialysis
- Volunteers with end stage renal disease who have received a renal transplantation within 1 year before screening
- Volunteers with end stage renal disease diagnosed with renal carcinoma within 1 year before screening
- Volunteers with end stage renal disease receiving immunosuppressive medications, including steroids
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Group 1 (normal kidney function)
Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
|
Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
Otros nombres:
|
Experimental: Group 2 (mild kidney impairment)
Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
|
Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
Otros nombres:
|
Experimental: Group 3 (moderate kidney impairment)
Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
|
Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
Otros nombres:
|
Experimental: Group 4 (severe kidney impairment)
Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
|
Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
Otros nombres:
|
Experimental: Group 5 (hemodialysis)
Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1 following completion of hemodialysis.
Approximately 10 days later, each volunteer will receive another single dose of canagliflozin before hemodialysis begins.
|
Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Plasma concentrations of canagliflozin (JNJ-28431754) in varying degrees of kidney function
Periodo de tiempo: Up to Day 6
|
Plasma concentrations of canagliflozin (JNJ-28431754) following the administration of a single dose of canagliflozin will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug) in varying degrees of kidney function.
|
Up to Day 6
|
Change from baseline in 24-hour urine glucose excretion in varying degrees of kidney function
Periodo de tiempo: Day -1 (Baseline) to Day 3
|
Change from baseline in 24-hour urine glucose excretion following the administration of a single dose of canagliflozin (JNJ-28431754) will be used to evaluate the pharmacodynamics of canagliflozin (ie, how the drug affects the body) in varying degrees of kidney function.
|
Day -1 (Baseline) to Day 3
|
Plasma concentrations of canagliflozin (JNJ-28431754) metabolites in varying degrees of kidney function
Periodo de tiempo: Up to Day 6
|
Plasma concentrations of canagliflozin (JNJ-28431754) metabolites following the administration of a single dose of canagliflozin will be used to determine pharmacokinetic parameters for canagliflozin metabolites (measurements describing how the body affects the metabolites) in varying degrees of kidney function.
|
Up to Day 6
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de marzo de 2008
Finalización primaria (Actual)
1 de noviembre de 2008
Finalización del estudio (Actual)
1 de noviembre de 2008
Fechas de registro del estudio
Enviado por primera vez
24 de diciembre de 2012
Primero enviado que cumplió con los criterios de control de calidad
28 de diciembre de 2012
Publicado por primera vez (Estimar)
3 de enero de 2013
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
29 de mayo de 2013
Última actualización enviada que cumplió con los criterios de control de calidad
27 de mayo de 2013
Última verificación
1 de mayo de 2013
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CR014761
- 28431754DIA1003 (Otro identificador: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Canagliflozin (JNJ-28431754)
-
Johnson & Johnson Pharmaceutical Research & Development...Terminado
-
Johnson & Johnson Pharmaceutical Research & Development...Terminado
-
Johnson & Johnson Pharmaceutical Research & Development...Terminado
-
Johnson & Johnson Pharmaceutical Research & Development...Terminado
-
Janssen Research & Development, LLCThe George Institute for Global Health, AustraliaTerminadoEnfermedades cardiovasculares | Diabetes Mellitus, Tipo 2 | Factores de riesgoEstados Unidos, Australia, Polonia, Ucrania, Reino Unido, Bélgica, Alemania, Francia, España, Argentina, Colombia, Israel, México, India, Canadá, Países Bajos, Suecia, Malasia, Nueva Zelanda, Estonia, Federación Rusa, Hungría, Noruega, L... y más
-
Johnson & Johnson Pharmaceutical Research & Development...Terminado
-
Johnson & Johnson Pharmaceutical Research & Development...Terminado
-
Johnson & Johnson Pharmaceutical Research & Development...Terminado
-
Johnson & Johnson Pharmaceutical Research & Development...Terminado
-
Johnson & Johnson Pharmaceutical Research & Development...Terminado